Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China.

Hedong ZhangQiuhao LiuShanbiao HuMingda ZhongFenghua PengYong GuoChunhua FangManhua NieLiang TanHelong DaiXubiao XieLongkai PengGongbin Lan

Published in: BioMed research international (2022)

Using a simplified genotyping/subtyping-free SOF/VEL treatment strategy, kidneys from hepatitis C viremic donors for both infected and uninfected recipients presented with safe, excellent, and comparable 1-year outcomes, which can safely expand the donor pool. HCV-positive donor kidneys should be utilized regularly, regardless of the recipient's HCV status.

Keyphrases

hepatitis c virus
human immunodeficiency virus
genome wide
high throughput
type diabetes
metabolic syndrome
gene expression
genetic diversity